The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [Lu]Lu-DOTATATE.

Purpose: In Peptide Receptor Radionuclide Therapy (PRRT) with [Lu]Lu-DOTATATE of gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) a question remains open about the potential benefits of personalised dosimetry. This observational prospective study examines the association of individualized dosimetry with progression free survival (PFS) in G1-G2 GEP NETs patients following the standard [Lu]Lu-DOTATATE therapeutic regimen.

Methods: The analysis was conducted on 42 patients administered 4 times, and on 165 lesions.

[F]FDG PET/CT: Lung Nodule Evaluation in Patients Affected by Renal Cell Carcinoma.

Renal Cell Carcinoma (RCC) is generally characterized by low-FDG avidity, and [F]FDG-PET/CT is not recommended to stage the primary tumor. However, its role to assess metastases is still unclear. The aim of this study was to evaluate the diagnostic accuracy of [F]FDG-PET/CT in correctly identifying RCC lung metastases using histology as the standard of truth.